Opaleye Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Opaleye Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-16,500	Closed	-$2.35M	–	45
2017 Q2	$2.35M	Buy	+16,500	New	+$2.55M	0.98%	26
2015 Q3	–	Sell	-3,250	Closed	-$3.08M	–	53
2015 Q2	$3.08M	Sell	3,250 -5,500	-63%	-$4.5M	1.23%	29
2015 Q1	$6.41M	Sell	8,750 -735	-8%	-$552K	2.98%	13
2014 Q4	$7.53M	Buy	9,485 +1,000	+12%	+$538K	3.81%	8
2014 Q3	$3.39M	Hold	8,485	–	–	2.64%	16
2014 Q2	$2.29M	Buy	8,485 +485	+6%	+$104K	1.97%	14
2014 Q1	$1.76M	Buy	8,000 +325	+4%	+$90.6K	1.3%	22
2013 Q4	$2M	Buy	+7,675	New	+$1.83M	1.57%	19

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Opaleye Management's TTPH Position: Q3 2017 in Review

Opaleye Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2017, closing a stake of 16,500 shares — an estimated $2.35M sold.

Opaleye Management first reported a position in TTPH in Q4 2013 and held it in 8 quarters. The position peaked at $7.53M in Q4 2014. 94 funds tracked by Wall St. Rank hold TTPH as of Q3 2017.

Opaleye Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Opaleye Management sold 16,500 Tetraphase Pharmaceuticals, Inc. shares in Q3 2017, an estimated $2.35M.
Opaleye Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2013 and held it in 8 quarters.
Opaleye Management's Tetraphase Pharmaceuticals, Inc. position peaked at $7.53M in Q4 2014.
94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2017.

Based on Opaleye Management's 13F filing for Q3 2017, filed 14 Nov 2017.